首页> 外文OA文献 >Significantly reduced genoprevalence of vaccine-type HPV-16/18 infections among vaccinated compared to non-vaccinated young women 5.5 years after a bivalent HPV-16/18 vaccine (Cervarix®) pilot project in Uganda
【2h】

Significantly reduced genoprevalence of vaccine-type HPV-16/18 infections among vaccinated compared to non-vaccinated young women 5.5 years after a bivalent HPV-16/18 vaccine (Cervarix®) pilot project in Uganda

机译:与未接种疫苗的年轻女性相比,疫苗型HpV-16/18感染的流行病学显着降低,这是乌干达二价HpV-16/18疫苗(Cervarix®)试点项目后的5.5年

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The objective of this study was to determine the prevalence and some predictors for vaccine and non-vaccine types of HPV infections among bivalent HPV vaccinated and non-vaccinated young women in Uganda. This was a comparative cross sectional study 5.5 years after a bivalent HPV 16/18 vaccination (Cervarix®, GlaxoSmithKline, Belgium) pilot project in western Uganda. Cervical swabs were collected between July 2014-August 2014 and analyzed with a HPV genotyping test, CLART® HPV2 assay (Genomica, Madrid Spain) which is based on PCR followed by microarray for determination of genotype. Blood samples were also tested for HIV and syphilis infections as well as CD4 and CD8 lymphocyte levels. The age range of the participants was 15-24 years and mean age was 18.6(SD 1.4). Vaccine-type HPV-16/18 strains were significantly less prevalent among vaccinated women compared to non-vaccinated women (0.5% vs 5.6%, p 0.006, OR 95% CI 0.08 (0.01-0.64). At type-specific level, significant difference was observed for HPV16 only. Other STIs (HIV/syphilis) were important risk factors for HPV infections including both vaccine types and non-vaccine types. In addition, for non-vaccine HPV types, living in an urban area, having a low BMI, low CD4 count and having had a high number of life time sexual partners were also significant risk factors. Our data concurs with the existing literature from other parts of the world regarding the effectiveness of bivalent HPV-16/18 vaccine in reducing the prevalence of HPV infections particularly vaccine HPV- 16/18 strains among vaccinated women. This study reinforces the recommendation to vaccinate young girls before sexual debut and integrate other STI particularly HIV and syphilis interventions into HPV vaccination packages.
机译:这项研究的目的是确定乌干达接受过二价HPV疫苗接种和未接种疫苗的年轻妇女中HPV疫苗和非疫苗类型感染的流行程度和一些预测因素。这是一项在乌干达西部进行的二价HPV 16/18疫苗接种(比利时的GlaxoSmithKline)试点项目5.5年后的一项比较性横断面研究。在2014年7月至2014年8月之间收集宫颈拭子,并用HPV基因分型测试,CLART®HPV2测定法(西班牙马德里Genomica,Geartica)进行分析,该方法基于PCR,然后通过微阵列测定基因型。还对血液样本进行了HIV和梅毒感染以及CD4和CD8淋巴细胞水平的检测。参与者的年龄范围是15-24岁,平均年龄是18.6(SD 1.4)。与未接种疫苗的女性相比,接种疫苗的女性中HPV-16 / 18疫苗株的患病率明显降低(0.5%比5.6%,P = 0.006,或95%CI 0.08(0.01-0.64)。其他性传播感染(HIV /梅毒)是包括疫苗类型和非疫苗类型在内的HPV感染的重要危险因素;此外,对于非疫苗型HPV类型,生活在城市地区且感染率较低体重指数(BMI),低CD4计数以及一生中有大量性伴侣也是重要的危险因素,我们的数据与世界其他地区的现有文献一致,有关二价HPV-16 / 18疫苗在降低患病率中的有效性这项研究加强了建议:在初次性生活前为年轻女孩接种疫苗,并将其他性传播感染特别是艾滋病毒和梅毒干预措施纳入HPV疫苗包装中。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号